$SCNX
Scienture Holdings, Inc. Stock $scnx

$scnx Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-K Financial Statement

#000149315224015595 Filed on April 22, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023
Revenue	$18.70K	$2.352M	$8.272M
YoY Change	-99.17%	-6.98%	-27.74%
Cost Of Revenue	$19.40K	$4.601M	$5.674M
YoY Change	-96.8%	366.47%	-5.39%
Gross Profit	-$703.00	-$2.249M	$2.598M
YoY Change	-100.04%	-245.77%	-52.34%
Gross Profit Margin	-3.76%	-95.59%	31.41%
Selling, General & Admin	$1.495M	$3.944M	$9.862M
YoY Change	-24.89%	116.66%	20.15%
% of Gross Profit			379.55%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$500.00	$499.8K	$19.38K
YoY Change	-82.27%	17623.05%	32.37%
% of Gross Profit			0.75%
Operating Expenses	$1.495M	$3.944M	$9.862M
YoY Change	-24.89%	116.66%	-0.14%
Operating Profit	-$1.496M	-$6.193M	-$7.263M
YoY Change	332.75%	2128.92%	64.17%
Interest Expense	$36.08K	-$703.4K	$1.198M
YoY Change	-80.04%	284.41%	256.43%
% of Operating Profit
Other Income/Expense, Net	-$129.1K	$309.4K	-$6.457M
YoY Change	-92.08%	-62.52%	-1355.21%
Pretax Income	-$1.625M	-$11.72M	-$13.72M
YoY Change	-17.73%	799.13%	250.92%
Income Tax
% Of Pretax Income
Net Earnings	-$1.834M	-$11.72M	-$17.84M
YoY Change	-7.14%	1166.33%	413.91%
Net Earnings / Revenue	-9807.49%	-498.04%	-215.7%
Basic Earnings Per Share	-$1.30		-$23.35
Diluted Earnings Per Share	-$1.30	-$12.57	-$7.49
COMMON SHARES
Basic Shares Outstanding	1.406M shares		764.1K shares
Diluted Shares Outstanding	1.406M shares		2.381M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$7.720M	$151.9K	$151.9K
YoY Change	935.46%	-86.6%	-86.6%
Cash & Equivalents	$7.720M	$151.9K
Short-Term Investments
Other Short-Term Assets	$874.1K	$107.8K	$107.8K
YoY Change	124.83%	-2.86%	-2.86%
Inventory	$6.439K	$968.00	$970.00
Prepaid Expenses	$797.4K	$107.8K
Receivables	$13.09K	$821.8K	$821.8K
Other Receivables	$2.231M	$1.671M	$1.671M
Total Short-Term Assets	$12.14M	$2.753M	$2.753M
YoY Change	479.67%	31.53%	31.53%
LONG-TERM ASSETS
Property, Plant & Equipment	$6.500K	$277.0K	$806.6K
YoY Change	-89.09%	324.77%	-27.79%
Goodwill
YoY Change
Intangibles		$8.963M
YoY Change
Long-Term Investments	$2.500M
YoY Change
Other Assets	$22.04K	$10.53K	$10.53K
YoY Change	-55.05%	-78.52%	-78.52%
Total Long-Term Assets	$2.704M	$9.780M	$9.780M
YoY Change	63.89%	504.85%	504.85%
TOTAL ASSETS
Total Short-Term Assets	$12.14M	$2.753M	$2.753M
Total Long-Term Assets	$2.704M	$9.780M	$9.780M
Total Assets	$14.85M	$12.53M	$12.53M
YoY Change	296.49%	237.81%	237.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$726.3K	$2.082M	$2.082M
YoY Change	-15.9%	185.54%	185.54%
Accrued Expenses	$500.5K	$401.0K	$540.7K
YoY Change	32.99%	38.27%	11.05%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due		$6.530M	$6.530M
YoY Change		3817.92%	3817.92%
Total Short-Term Liabilities	$2.902M	$11.56M	$11.56M
YoY Change	-31.92%	438.31%	438.31%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$25.00K	$25.00K
YoY Change		-92.5%	-92.5%
Other Long-Term Liabilities	$161.0K	$409.2K	$409.2K
YoY Change	-79.27%	-53.87%	-53.87%
Total Long-Term Liabilities	$161.0K	$434.2K	$434.2K
YoY Change	-79.27%	-51.05%	-64.42%
TOTAL LIABILITIES
Total Short-Term Liabilities	$2.902M	$11.56M	$11.56M
Total Long-Term Liabilities	$161.0K	$434.2K	$434.2K
Total Liabilities	$3.063M	$11.99M	$11.99M
YoY Change	-39.22%	256.1%	306.89%
SHAREHOLDERS EQUITY
Retained Earnings	-$26.50M	-$33.25M
YoY Change	21.03%	68.76%
Common Stock	$14.00	$9.00
YoY Change	100.0%	-90.91%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$11.79M	$542.4K	$542.4K
YoY Change
Total Liabilities & Shareholders Equity	$14.85M	$12.53M	$12.53M
YoY Change	296.49%	237.81%	237.81%

Cashflow Statement

Concept	2024 Q2	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.834M	-$11.72M	-$17.84M
YoY Change	-7.14%	1166.33%	413.91%
Depreciation, Depletion And Amortization	$500.00	$499.8K	$19.38K
YoY Change	-82.27%	17623.05%	32.37%
Cash From Operating Activities	$4.222M	-$867.5K	-$2.074M
YoY Change	1184.99%	-170.53%	35.89%
INVESTING ACTIVITIES
Capital Expenditures	$0.00
YoY Change	-100.0%
Acquisitions
YoY Change
Other Investing Activities	-$770.00	-$350.0K	-$275.7K
YoY Change			-1298.78%
Cash From Investing Activities	-$770.00	-$350.0K	-$275.7K
YoY Change	-98.51%	204.48%	-35.56%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			$0.00
YoY Change			-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	0.000	1.335M	1.406M
YoY Change	-100.0%	-540.45%	-4098.55%
NET CHANGE
Cash From Operating Activities	4.222M	-867.5K	-2.074M
Cash From Investing Activities	-770.0	-350.0K	-275.7K
Cash From Financing Activities	0.000	1.335M	1.406M
Net Change In Cash	4.221M	117.9K	-$943.0K
YoY Change	-1041.11%	-85.48%	-52.59%
FREE CASH FLOW
Cash From Operating Activities	$4.222M	-$867.5K	-$2.074M
Capital Expenditures	$0.00
Free Cash Flow	$4.222M
YoY Change	1425.55%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Auditor Firm AuditorFirmId	206
CY2022Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent		usd
CY2022Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent		usd
CY2023Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill		usd
CY2023Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent		usd
CY2022Q4	MEDS	Purchase Price Payable PurchasePricePayable		usd
CY2023Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Minority Interest MinorityInterest		usd
CY2023	MEDS	Loss On Inventory Investment LossOnInventoryInvestment		usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1		usd
CY2022	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest		usd
CY2023	MEDS	Stock Issued During Period Value Reverse Stock Splits StockIssuedDuringPeriodValueReverseStockSplits		shares
CY2023	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
CY2023	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill		usd
CY2023	us-gaap	Inventory Write Down InventoryWriteDown		usd
CY2022	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss		usd
CY2023	MEDS	Loss On Inventory Investments LossOnInventoryInvestments		usd
CY2022	MEDS	Loss On Inventory Investments LossOnInventoryInvestments		usd
CY2023	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets		usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2022	MEDS	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets		usd
CY2022	MEDS	Increase Decrease In Purchase Price Payable IncreaseDecreaseInPurchasePricePayable		usd
CY2022	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross		usd
CY2023	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
CY2023	us-gaap	Payments For Software PaymentsForSoftware		usd
CY2022	us-gaap	Payments For Software PaymentsForSoftware		usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt		usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022	MEDS	Proceeds From Securities Purchase Agreement ProceedsFromSecuritiesPurchaseAgreement		usd
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet		usd
CY2023	us-gaap	Notes Issued1 NotesIssued1		usd
CY2022	MEDS	Note Cancelled From Related Party Agreement Termination NoteCancelledFromRelatedPartyAgreementTermination		usd
CY2023	MEDS	Intangible Asset Contribution From Noncontrolling Interest IntangibleAssetContributionFromNoncontrollingInterest		usd
CY2022	MEDS	Disposition Of Related Party Assets DispositionOfRelatedPartyAssets		usd
CY2022	MEDS	Issuance Of Notes Receivable IssuanceOfNotesReceivable		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023	MEDS	Disposal Group Including Discontinued Operation Impairment Of Intangible Asset DisposalGroupIncludingDiscontinuedOperationImpairmentOfIntangibleAsset		usd
CY2023	MEDS	Disposal Group Including Discontinued Operation Gain Loss On Disposal Of Asset DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposalOfAsset		usd
CY2023	MEDS	Disposal Group Including Discontinued Operation Other Income Expenses DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses		usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials		usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods		usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
CY2022	us-gaap	Adjustment For Amortization AdjustmentForAmortization		usd
CY2023Q4	us-gaap	Deferred Revenue DeferredRevenue		usd
CY2022Q4	MEDS	Other Payables OtherPayables		usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	MEDS	Deferred Tax Assets Purchased Intangibles DeferredTaxAssetsPurchasedIntangibles		usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther		usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets		usd
CY2022Q4	MEDS	Deferred Tax Assets Right To Use Assets DeferredTaxAssetsRightToUseAssets		usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities		usd
CY2023Q4	MEDS	Net Deferred Taxes NetDeferredTaxes		usd
CY2022Q4	MEDS	Net Deferred Taxes NetDeferredTaxes		usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-39199
CY2023	dei	Entity Registrant Name EntityRegistrantName	TRxADE HEALTH, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	46-3673928
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	2420 Brunello Trace
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Lutz
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	FL
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	33558
CY2023	dei	City Area Code CityAreaCode	(800)
CY2023	dei	Local Phone Number LocalPhoneNumber	261-0281
CY2023	dei	Security12b Title Security12bTitle	Common Stock, $0.00001 Par Value Per Share
CY2023	dei	Trading Symbol TradingSymbol	MEDS
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	11457013	usd
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	1406348	shares
CY2023	dei	Auditor Firm AuditorFirmId	6866
CY2023	dei	Auditor Name AuditorName	CM3 Advisory
CY2023	dei	Auditor Location AuditorLocation	San Diego, California
CY2022	dei	Auditor Name AuditorName	MaloneBailey, LLP
CY2022	dei	Auditor Location AuditorLocation	Houston, Texas
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	151908	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1094894	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	821804	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	629921	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	968	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	65523	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	107774	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	104461	usd
CY2023Q4	us-gaap	Notes And Loans Receivable Net Current NotesAndLoansReceivableNetCurrent	1300000	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	370608	usd
CY2022Q4	us-gaap	Assets Of Disposal Group Including Discontinued Operation Current AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent	198324	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	2753062	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2093123	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	277009	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65214	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	8962688	usd
CY2023Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	10531	usd
CY2022Q4	us-gaap	Deposits Assets Noncurrent DepositsAssetsNoncurrent	49029	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	529623	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	1051815	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	450845	usd
CY2023Q4	us-gaap	Assets Assets	12532913	usd
CY2022Q4	us-gaap	Assets Assets	3710026	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2082054	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	527984	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	400987	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	271230	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	70310	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	67517	usd
CY2023Q4	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities	1246346	usd
CY2022Q4	MEDS	Contingent Funding Liabilities ContingentFundingLiabilities	108036	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	139705	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	196872	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	6530000	usd
CY2022Q4	us-gaap	Notes Payable Current NotesPayableCurrent	166667	usd
CY2023Q4	MEDS	Warrant Liability WarrantLiability	736953	usd
CY2022Q4	MEDS	Warrant Liability WarrantLiability	588533	usd
CY2023Q4	MEDS	Purchase Price Payable PurchasePricePayable	350000	usd
CY2022Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	219952	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11556355	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2146791	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	409205	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	887035	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	25000	usd
CY2022Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	333333	usd
CY2023Q4	us-gaap	Liabilities Liabilities	11990560	usd
CY2022Q4	us-gaap	Liabilities Liabilities	3367159	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	905008	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	905008	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	626247	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	626247	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	9	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	6	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	33788284	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	20482666	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33245940	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-19719536	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	542353	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	763136	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-420269	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	542353	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	342867	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12532913	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	3710026	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8272214	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10250168	usd
CY2023	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	5673957	usd
CY2022	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	4730897	usd
CY2023	us-gaap	Gross Profit GrossProfit	2598257	usd
CY2022	us-gaap	Gross Profit GrossProfit	5519271	usd
CY2022	MEDS	Loss On Inventory Investment LossOnInventoryInvestment	875250	usd
CY2023	us-gaap	Salaries And Wages SalariesAndWages	2698178	usd
CY2022	us-gaap	Salaries And Wages SalariesAndWages	3581089	usd
CY2023	us-gaap	Professional Fees ProfessionalFees	1466567	usd
CY2022	us-gaap	Professional Fees ProfessionalFees	466735	usd
CY2023	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	1534377	usd
CY2022	us-gaap	Litigation Settlement Expense LitigationSettlementExpense	829751	usd
CY2023	MEDS	Technology Expense TechnologyExpense	1376908	usd
CY2022	MEDS	Technology Expense TechnologyExpense	993185	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2785633	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1689230	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	9861663	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	8435240	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-7263406	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-2915969	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	542353	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-13720546	usd
CY2022	MEDS	Change In Fair Value Of Warrant Liability ChangeInFairValueOfWarrantLiability	825544	usd
CY2023	us-gaap	Interest Income Other InterestIncomeOther	4198	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5129115	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	2200	usd
CY2023	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	14543	usd
CY2023	us-gaap	Interest Expense InterestExpense	1198346	usd
CY2022	us-gaap	Interest Expense InterestExpense	336206	usd
CY2023	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-13720546	usd
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-4123028	usd
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax IncomeLossFromDiscontinuedOperationsNetOfTax	-1506426	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-17843574	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3909868	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-17843574	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-3472099	usd
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-437769	usd
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-17.96
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-3.48
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-5.76
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-3.47
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-5.40
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-2.67
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.73
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-2.66
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-23.35
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.15
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.49
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.13
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	764058	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	564862	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2381443	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	566609	shares
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	3770173	usd
CY2022	MEDS	Noncontrolling Interest Of Capital Contributions NoncontrollingInterestOfCapitalContributions	792500	usd
CY2022	MEDS	Noncontrolling Interest Of Capital Distributions NoncontrollingInterestOfCapitalDistributions	-775000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	254106	usd
CY2022	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	130918	usd
CY2022	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	875	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	79163	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3909868	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	342867	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	342867	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	257772	usd
CY2023	MEDS	Stock Issued During Period Value Warrants Exercised For Cash StockIssuedDuringPeriodValueWarrantsExercisedForCash	1622	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	29738	usd
CY2023	MEDS	Disposition Of Assets DispositionOfAssets	4737439	usd
CY2023	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	12500089	usd
CY2023	MEDS	Stock Issued During Period Value Shares Issued Pursuant To Securities Purchase Agreement StockIssuedDuringPeriodValueSharesIssuedPursuantToSecuritiesPurchaseAgreement	516400	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-17843574	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	542353	usd
CY2022	us-gaap	Income Loss From Continuing Operations IncomeLossFromContinuingOperations	-2403442	usd
CY2023	us-gaap	Depreciation Depreciation	19375	usd
CY2022	us-gaap	Depreciation Depreciation	13486	usd
CY2023	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	29738	usd
CY2022	us-gaap	Stock Option Plan Expense StockOptionPlanExpense	79163	usd
CY2023	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	257772	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	254106	usd
CY2022	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-246683	usd
CY2022	us-gaap	Impairment Of Intangible Assets Excluding Goodwill ImpairmentOfIntangibleAssetsExcludingGoodwill	792500	usd
CY2022	us-gaap	Inventory Write Down InventoryWriteDown	875250	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5129115	usd
CY2022	us-gaap	Gain Loss On Disposition Of Assets GainLossOnDispositionOfAssets	2200	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	215665	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	181218	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	814790	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	293784	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-369932	usd
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-38367	usd
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-335066	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-4232947	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	51737	usd
CY2023	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	254924	usd
CY2022	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	875250	usd
CY2023	MEDS	Increase Decrease In Right Of Use Assets IncreaseDecreaseInRightOfUseAssets	-306527	usd
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-534997	usd
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-164618	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1607625	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	199833	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	58692	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-211694	usd
CY2023	MEDS	Increase Decrease In Purchase Price Payable IncreaseDecreaseInPurchasePricePayable	-350000	usd
CY2023	MEDS	Increase Decrease In Current Liabilities IncreaseDecreaseInCurrentLiabilities	2794	usd
CY2022	MEDS	Increase Decrease In Current Liabilities IncreaseDecreaseInCurrentLiabilities	67517	usd
CY2023	MEDS	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	148420	usd
CY2022	MEDS	Increase Decrease In Warrant Liability IncreaseDecreaseInWarrantLiability	588533	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-1592424	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-199020	usd
CY2023	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-481177	usd
CY2022	us-gaap	Cash Provided By Used In Operating Activities Discontinued Operations CashProvidedByUsedInOperatingActivitiesDiscontinuedOperations	-1365648	usd
CY2023	us-gaap	Payments To Acquire Businesses Gross PaymentsToAcquireBusinessesGross	344454	usd
CY2022	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	749	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-344454	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	749	usd
CY2023	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	68737	usd
CY2022	us-gaap	Cash Provided By Used In Investing Activities Discontinued Operations CashProvidedByUsedInInvestingActivitiesDiscontinuedOperations	-428594	usd
CY2023	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	400000	usd
CY2023	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	150000	usd
CY2023	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	1043107	usd
CY2022	us-gaap	Payment For Contingent Consideration Liability Financing Activities PaymentForContingentConsiderationLiabilityFinancingActivities	716964	usd
CY2023	MEDS	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue	2181417	usd
CY2022	MEDS	Proceeds From Sale Of Future Revenue ProceedsFromSaleOfFutureRevenue	825000	usd
CY2023	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	1622	usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	875	usd
CY2023	MEDS	Proceeds From Securities Purchase Agreement ProceedsFromSecuritiesPurchaseAgreement	516400	usd
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	130918	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	1906332	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	239829	usd
CY2023	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-500000	usd
CY2022	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-275000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-942986	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2027684	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1094894	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	3122578	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	151908	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1094894	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	733694	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	336206	usd
CY2023	MEDS	Insurance Premium Financed InsurancePremiumFinanced	306152	usd
CY2022	MEDS	Insurance Premium Financed InsurancePremiumFinanced	220354	usd
CY2022	us-gaap	Notes Issued1 NotesIssued1	500000	usd
CY2023	MEDS	Note Cancelled From Related Party Agreement Termination NoteCancelledFromRelatedPartyAgreementTermination	500000	usd
CY2022	MEDS	Intangible Asset Contribution From Noncontrolling Interest IntangibleAssetContributionFromNoncontrollingInterest	792500	usd
CY2023	MEDS	Disposition Of Related Party Assets DispositionOfRelatedPartyAssets	492030	usd
CY2023	MEDS	Issuance Of Notes Receivable IssuanceOfNotesReceivable	1300000	usd
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	Effective June 21, 2023, the Company executed a 1:15 reverse stock split for stockholders of record on that date
CY2023Q2	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1.00
CY2022Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	0	usd
CY2023Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	370608	usd
CY2023	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5129115	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	218729	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-23.35
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-6.15
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-7.49
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-6.13
CY2023	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-17.96
CY2022	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-3.48
CY2023	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-5.76
CY2022	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-3.47
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-5.40
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-2.67
CY2023	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-1.73
CY2022	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-2.66
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-33245940	usd
CY2023Q4	MEDS	Working Capital WorkingCapital	8803293	usd
CY2023Q4	us-gaap	Cash Cash	151908	usd
CY2023	MEDS	Gain Loss On Disposal Of Assets GainLossOnDisposalOfAssets	3300225.42	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	851755	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Revenue DisposalGroupIncludingDiscontinuedOperationRevenue	1198097	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	705206	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Costs Of Goods Sold DisposalGroupIncludingDiscontinuedOperationCostsOfGoodsSold	1266152	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	146549	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Gross Profit Loss DisposalGroupIncludingDiscontinuedOperationGrossProfitLoss	-68055	usd
CY2022	MEDS	Disposal Group Including Discontinued Operation Impairment Of Intangible Asset DisposalGroupIncludingDiscontinuedOperationImpairmentOfIntangibleAsset	792500	usd
CY2023	MEDS	Disposal Group Including Discontinued Operation Wages And Salary Expense DisposalGroupIncludingDiscontinuedOperationWagesAndSalaryExpense	456297	usd
CY2022	MEDS	Disposal Group Including Discontinued Operation Wages And Salary Expense DisposalGroupIncludingDiscontinuedOperationWagesAndSalaryExpense	360386	usd
CY2023	MEDS	Disposal Group Including Discontinued Operation Professional Expense DisposalGroupIncludingDiscontinuedOperationProfessionalExpense	23371	usd
CY2022	MEDS	Disposal Group Including Discontinued Operation Professional Expense DisposalGroupIncludingDiscontinuedOperationProfessionalExpense	52907	usd
CY2023	MEDS	Disposal Group Including Discontinued Operation Accounting And Legal Expense DisposalGroupIncludingDiscontinuedOperationAccountingAndLegalExpense	70773	usd
CY2022	MEDS	Disposal Group Including Discontinued Operation Accounting And Legal Expense DisposalGroupIncludingDiscontinuedOperationAccountingAndLegalExpense	604	usd
CY2023	MEDS	Disposal Group Including Discontinued Operation Technology Expense DisposalGroupIncludingDiscontinuedOperationTechnologyExpense	30075	usd
CY2022	MEDS	Disposal Group Including Discontinued Operation Technology Expense DisposalGroupIncludingDiscontinuedOperationTechnologyExpense	167671	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	36592	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation General And Administrative Expense DisposalGroupIncludingDiscontinuedOperationGeneralAndAdministrativeExpense	66203	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	617108	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Operating Expense DisposalGroupIncludingDiscontinuedOperationOperatingExpense	1440271	usd
CY2023	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-470559	usd
CY2022	us-gaap	Disposal Group Including Discontinued Operation Operating Income Loss DisposalGroupIncludingDiscontinuedOperationOperatingIncomeLoss	-1508326	usd
CY2022	MEDS	Disposal Group Including Discontinued Operation Gain Loss On Disposal Of Asset DisposalGroupIncludingDiscontinuedOperationGainLossOnDisposalOfAsset	1900	usd
CY2022	MEDS	Disposal Group Including Discontinued Operation Other Income Expenses DisposalGroupIncludingDiscontinuedOperationOtherIncomeExpenses	1900	usd
CY2023	MEDS	Disposal Group Including Discontinued Operation Other Income Loss From Discontinued Opeations DisposalGroupIncludingDiscontinuedOperationOtherIncomeLossFromDiscontinuedOpeations	-470559	usd
CY2022	MEDS	Disposal Group Including Discontinued Operation Other Income Loss From Discontinued Opeations DisposalGroupIncludingDiscontinuedOperationOtherIncomeLossFromDiscontinuedOpeations	-1506426	usd
CY2023Q4	MEDS	Annual Base Salary AnnualBaseSalary	400000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8272214	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10250168	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	65523	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	968	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	968	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	65523	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	4030755	usd
CY2023Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	24893624	usd
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	Effective June 21, 2023, the Company executed a 1:15 reverse stock split for stockholders of record on that date. This was executed to comply with the Nasdaq Listing Rule 5550(a)(2) to have the price of the stock above $1
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	814790	usd
CY2023	us-gaap	Adjustment For Amortization AdjustmentForAmortization	814790	usd
CY2023Q4	MEDS	Insurance Refunds Payable InsuranceRefundsPayable	62390	usd
CY2022Q4	MEDS	Insurance Refunds Payable InsuranceRefundsPayable	62390	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	5127	usd
CY2023Q4	MEDS	Other Payables OtherPayables	7920	usd
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	70310	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	67517	usd
CY2023Q4	us-gaap	Notes Payable Current NotesPayableCurrent	6530000	usd
CY2023Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	25000	usd
CY2023Q4	us-gaap	Notes Payable NotesPayable	6555000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	90869	usd
CY2023	MEDS	Schedule Of Income Loss Before Income Taxes ScheduleOfIncomeLossBeforeIncomeTaxes	<p id="xdx_89A_ecustom--ScheduleOfIncomeLossBeforeIncomeTaxes_zLsbad5hR4fg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income (loss) before income taxes for the years ended December 31, 2023 and 2022 consisted of the following:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><span id="xdx_8BD_zBucjkW0Rbdk" style="display: none">SCHEDULE OF INCOME (LOSS) BEFORE INCOME TAXES</span></span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>For the year ended December 31,</b></span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_495_20230101__20231231_zJwcWcPtfMNg" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" id="xdx_493_20220101__20221231_zKOfcpUIT5yc" style="border-bottom: Black 1.5pt solid; font: bold 10pt Times New Roman, Times, Serif; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"> <td style="font: 10pt Times New Roman, Times, Serif"> </td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td colspan="2" style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: bold 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td></tr> <tr id="xdx_408_eus-gaap--IncomeLossFromContinuingOperations_hus-gaap--IncomeTaxAuthorityAxis__us-gaap--DomesticCountryMember_zDG9l3nWIxme" style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font: 10pt Times New Roman, Times, Serif; width: 64%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">US</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(17,843,574</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 2%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td> <td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 14%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(3,909,868</span></td><td style="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> </table>
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	5800214	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	4030755	usd
CY2023Q4	MEDS	Deferred Tax Assets Purchased Intangibles DeferredTaxAssetsPurchasedIntangibles	151877	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	127896	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	6079987	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4030755	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	-15534	usd
CY2023Q4	MEDS	Deferred Tax Assets Right To Use Assets DeferredTaxAssetsRightToUseAssets	-127896	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	143430	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	5936557	usd
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	1
CY2023	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Warrant Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionWarrantInstrumentsGranted	41193	shares
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures And Expirations ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations	0	shares
CY2021Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number Split Adjusted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumberSplitAdjusted	2969	shares
CY2021Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	4.82
CY2022	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning	P0Y11M12D
CY2021Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	11135	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	177536	shares
CY2022	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	22.50
CY2022	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageRemainingContractualTerm	P4Y9M7D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeitures ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitures	202	shares
CY2022	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Forfeited In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeitedInPeriodWeightedAverageExercisePrice	3.90
CY2022	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Split Adjusted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedSplitAdjusted	972	shares
CY2022	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	0.06
CY2022Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number Split Adjusted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumberSplitAdjusted	179331	shares
CY2022Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	22.50
CY2023	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Beginning ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning	P4Y8M19D
CY2022Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Options Equity Instrument Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue	6731	usd
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted	41193	shares
CY2023	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice	7.20
CY2023	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Granted In Period Weighted Average Remaining Contractual Term ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageRemainingContractualTerm	P4Y9M3D
CY2023	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised Split Adjusted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisedSplitAdjusted	1795	shares
CY2023	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice	0.90
CY2023Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number Split Adjusted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumberSplitAdjusted	218729	shares
CY2023Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	19.62
CY2023	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Remaining Contractual Term Ending ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding	P3Y11M12D
CY2023Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Exercisable Number Split Adjusted ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableNumberSplitAdjusted	218279	shares
CY2023Q4	MEDS	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableWeightedAverageExercisePrice	19.62
CY2023	MEDS	Sharebased Compensation Arrangement By Sharebased Payment Award Non Option Equity Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableWeightedAverageRemainingContractualTerm1	P3Y11M12D
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	29738	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	79163	usd
CY2023	us-gaap	Loss Contingency Disclosures LossContingencyDisclosures	<p id="xdx_80C_eus-gaap--LossContingencyDisclosures_zyvWV9Za4UH1" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 17 – <span id="xdx_82C_zvYl9KAibVL9">CONTINGENCIES</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Studebaker Defense Group, LLC</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In July 2020, the Company’s wholly-owned subsidiary, IPS, entered into an agreement with Studebaker Defense Group, LLC (“Studebaker”) wherein IPS would pay Studebaker a down payment of $<span id="xdx_90B_ecustom--DownPayment_c20200701__20200731__dei--LegalEntityAxis__custom--IPSMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember_zHx6JaOl3OL4" title="Down payment">500,000</span> and Studebaker would deliver <span id="xdx_90C_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200813__20200814__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IntegraMember_zz2G7efhlxV9" title="Number of nitrile gloves delivered">180,000</span> boxes of nitrile gloves by August 14, 2020. IPS wired the $<span id="xdx_90E_eus-gaap--LossContingencyDamagesSoughtValue_c20200701__20200731__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IPSMember_zsRYOXALVFN7" title="Loss contingency damages sought value">500,000</span> to Studebaker, but to date, Studebaker has not delivered the gloves or provided a refund of the deposit. In December 2020, the Company filed a complaint against Studebaker in Florida state court, Case No. 20-CA-010118 in the Circuit Court for the Thirteenth Judicial Circuit in Hillsborough County, for among other things, breach of contract. Studebaker did not answer the complaint, nor did counsel for Studebaker file an appearance. Accordingly, in February 2021, the Company filed for a default judgment; however, on March 22, 2021, counsel for Studebaker filed an appearance and shortly thereafter filed a motion to vacate the default judgment and dismiss the complaint on jurisdictional grounds. The court granted Studebaker’s motion to set aside the default judgment but denied the motion to dismiss. At June 30, 2021, the $<span id="xdx_907_ecustom--LossOnInventoryInvestment_c20210101__20210630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--StudebakerDefenseGroupLLCMember__dei--LegalEntityAxis__custom--IPSMember_zFEgGpr7uRXl" title="Loss on inventory investment">500,000</span> was recorded as Loss on Inventory Investment. The Company won this case but has not collected any settlement yet, another lawsuit was filed to collect.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On April 13, 2023, a settlement was reached in the Studebaker and IPS legal case. The court found in favor of IPS and ordered Studebaker to pay $<span id="xdx_90B_eus-gaap--RepaymentsOfRelatedPartyDebt_c20230412__20230413_zRd6N9jPiUmk" title="Repayments of related party debt">550,000</span> to IPS. The payments were to commence on May 1, 2023 and continue monthly in 17 installments until the full amount is paid in full but as of the filing date, no payment has been received by IPS.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>Sandwave Group Dsn Bhd and Crecom Burj Group SDN BHD</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In August 2020, IPS entered into an agreement with Sandwave Group Dsn Bhd (“Sandwave”), wherein IPS would pay Sandwave a down payment of $<span id="xdx_906_ecustom--DownPayment_c20200801__20200831__dei--LegalEntityAxis__custom--IPSMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_z03jLwc9InP7" title="Down payment">581,250</span> and Sandwave’s supplier, Crecom Burj Group SDN BHD (“Crecom”), would deliver <span id="xdx_903_ecustom--NumberOfNitrileGlovesDelivered_uInteger_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember__dei--LegalEntityAxis__custom--IPSMember_zSIGZRAXFRl8" title="Number of nitrile gloves delivered">150,000</span> boxes of nitrile gloves within 45 days. IPS wired the $<span id="xdx_90E_eus-gaap--LossContingencyDamagesSoughtValue_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember__dei--LegalEntityAxis__custom--IPSMember_zRPb7ShIHUE4" title="Loss contingency damages sought value">581,250</span> to Sandwave, which in turn wired the purchase price to Crecom, which Crecom accepted; however, to date, Crecom has not delivered the nitrile gloves. IPS demanded return of its $<span id="xdx_90A_eus-gaap--LossContingencyDamagesSoughtValue_c20200801__20200831__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--CrecomBurjGroupSdnBhdMember__dei--LegalEntityAxis__custom--IPSMember_zayRNWaHC1fk" title="Loss contingency damages sought value">581,250</span> and Crecom acknowledged that IPS was entitled to a refund. As of February 2021, Crecom had not returned any funds and IPS filed a complaint against Crecom in Malaysia: Case No. WA-22NCC-55-02/2021 in the High Court of Malaysia at Kuala Lumpur in the Federal Territory, Malaysia for the Malaysian equivalent of breach of contract. On September 1, 2022 counsel for Crecom informed the court that Crecom had been wound up on August 23, 2022; under Section 471 of the Malaysian Companies Act 2016, the suit filed by IPS was stayed until leave of the court is obtained to proceed. Given this new information regarding Crecom the Company has decided at this time to stop its pursuit of this lawsuit until or unless additional information is obtained by counsel for IPS. At June 30, 2021, the $<span id="xdx_908_ecustom--LossOnInventoryInvestment_c20210101__20210630__dei--LegalEntityAxis__custom--IPSMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--SandwaveGroupDsnBhdMember_zOXA5ebsytP7" title="Loss on inventory investment">581,250</span> was recorded as Loss on Inventory Investment.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><i>GSG PPE, LLC</i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On November 19, 2021, IPS filed a complaint against GSG PPE, LLC (“GSG”) and Gary Waxman (“Waxman”), the owner, alleging three counts of breach of contract for a purchase agreement, a promissory note, and a personal guaranty. Collectively, the company alleges that GSG and Waxman have materially breached all three contracts. In late 2020, GSG and IPS executed a valid initial contract setting the terms of a business transaction. GSG failed to pay IPS approximately 75% of the amount owed to IPS. GSG acknowledged it owed the money and executed a promissory note in favor of IPS in the amount of $<span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20210930_zfG0x3fZFzCg" title="Principal amount">630,000</span> which matured on September 30, 2021. The note provides for attorney fees and interest in addition to the $<span id="xdx_904_ecustom--AttorneyFees_c20230101__20231231_zAQmzhUwsw7c" title="Attorney fees">630,000</span>. Waxman’s personal guaranty confirmed that GSG owed IPS $<span id="xdx_90E_eus-gaap--DebtInstrumentFaceAmount_iI_c20231231__srt--TitleOfIndividualAxis__custom--WaxmanMember_z4ryXP06Z5Pd" title="Principal amount">630,000</span>. On September 30, 2021, the $<span id="xdx_909_eus-gaap--ProvisionForDoubtfulAccounts_c20210928__20210930_zO4oruefeq2k" title="Bad debt expenses">630,000</span> was recorded as Bad Debt Expense. A settlement was entered into between the parties in June 2022, whereby GSG and Waxman agreed to pay $<span id="xdx_903_eus-gaap--LegalFees_c20220601__20220630_zTGpbIVxFqsc" title="Attorney fees">743,000</span> which included attorney fees and interest, which is required to be paid to the Company in monthly installments over 17 months. The Company received additional monthly installment payments as part of the agreement through January 2023. As of December 31, 2023, and through the date of this filing, the Company has not received the monthly installment payments due to the Company from GSG since January of 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q2	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	550000	usd
CY2021Q3	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	630000	usd
CY2023	MEDS	Attorney Fees AttorneyFees	630000	usd
CY2021Q3	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	630000	usd
CY2022Q2	us-gaap	Legal Fees LegalFees	743000	usd
CY2022Q1	MEDS	Increase In Right Of Use Asset IncreaseInRightOfUseAsset	977220	usd
CY2022Q1	us-gaap	Security Deposit SecurityDeposit	38500	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	642887	usd
CY2022Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	664992	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	313301	usd
CY2023Q4	MEDS	Operating Lease Liability Right Of Use Assets OperatingLeaseLiabilityRightOfUseAssets	351581	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	187935	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	193487	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	163146	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	58347	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	48612	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	651527	usd
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	102617	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	548910	usd
CY2023Q4	MEDS	Lease Obligation Current LeaseObligationCurrent	139705	usd
CY2023Q4	MEDS	Operating Lease Liabilities Noncurrent OperatingLeaseLiabilitiesNoncurrent	409205	usd
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.10	pure
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y7M6D
CY2023Q4	us-gaap	Short Term Lease Commitment Amount ShortTermLeaseCommitmentAmount	187361	usd
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	385977	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	344525	usd
CY2023	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	215665	usd
CY2022	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	181218	usd
CY2023	MEDS	Payment For Operating Lease Liabilities PaymentForOperatingLeaseLiabilities	195475	usd
CY2022	MEDS	Payment For Operating Lease Liabilities PaymentForOperatingLeaseLiabilities	164618	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	8272214	usd
CY2023	us-gaap	Gross Profit GrossProfit	2598257	usd
CY2023Q4	us-gaap	Assets Assets	12532913	usd
CY2023	us-gaap	Profit Loss ProfitLoss	-17843574	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	5673957	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	10250168	usd
CY2022	us-gaap	Gross Profit GrossProfit	5519271	usd
CY2022Q4	us-gaap	Assets Assets	3710026	usd
CY2022	us-gaap	Profit Loss ProfitLoss	-3909868	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	4730897	usd
CY2024Q1	MEDS	Special Cash Dividend SpecialCashDividend	8.00	usd
CY2023Q4	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023Q4	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023Q4	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-015595-index-headers.html	Edgar Link	pending
R31.htm	Edgar Link	pending
0001493152-24-015595-index.html	Edgar Link	pending
0001493152-24-015595.txt	Edgar Link	pending
0001493152-24-015595-xbrl.zip	Edgar Link	pending
ex19-1.htm	Edgar Link	pending
ex19-1_001.jpg	Edgar Link	pending
ex19-1_002.jpg	Edgar Link	pending
ex19-1_003.jpg	Edgar Link	pending
ex19-1_004.jpg	Edgar Link	pending
ex19-1_005.jpg	Edgar Link	pending
ex19-1_006.jpg	Edgar Link	pending
ex19-1_007.jpg	Edgar Link	pending
ex19-1_008.jpg	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex23-1.htm	Edgar Link	pending
ex23-2.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
meds-20231231.xsd	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
meds-20231231_def.xml	Edgar Link	unprocessable
meds-20231231_pre.xml	Edgar Link	unprocessable
meds-20231231_lab.xml	Edgar Link	unprocessable
form10-k_htm.xml	Edgar Link	completed
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
meds-20231231_cal.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SCNX
Scienture Holdings, Inc. Stock $scnx

2024 Q2 Form 10-K Financial Statement

#000149315224015595 Filed on April 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX Scienture Holdings, Inc. Stock $scnx

2024 Q2 Form 10-K Financial Statement

#000149315224015595 Filed on April 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SCNX
Scienture Holdings, Inc. Stock $scnx